A pilot study to evaluate early predictive value of thorax perfusion-CT in advanced NSCLC

Aya, Francisco; Benegas, Mariana; Viñolas, Nuria; Reyes, Roxana; Vollmer, Ivan; Arcocha, Ainara; Sánchez, Marcelo; Reguart, Noemí

doi:http://dx.doi.org/10.3390/cancers13215566

A pilot study to evaluate early predictive value of thorax perfusion-CT in advanced NSCLC

License

Citation

Aya F, Benegas M, Viñolas N, Reyes R, Vollmer I, Arcocha A et al. A pilot study to evaluate early predictive value of thorax perfusion-CT in advanced NSCLC. Cancers (Basel). 2021 Nov 6;13(21):5566. DOI: 10.3390/cancers13215566

Abstract

Background: The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. Methods: In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine the ability of pCT to detect early changes in blood flow (BF), blood volume (BV), and permeability (PMB), and to explore whether these changes could predict the response at day +42 in patients with advanced, treatment-naive, non-squamous NSCLC treated with cisplatin and gemcitabine plus bevacizumab. Results: All of the perfusion parameters showed a consistent decrease during the course of treatment. The BV difference between baseline and early assessment was significant (p = 0.013), whereas all perfusion parameters showed significant differences between baseline and day +42 (p = 0.003, p = 0.049, and p = 0.002, respectively). Among the 16 patients evaluable for efficacy, a significant decline in BV at day +7 from baseline was observed in tumors with no response (p = 0.0418). Conclusions: Our results confirm that pCT can capture early changes in tumor vasculature. A substantial early decline of BV from baseline might identify tumors less likely responsive to antiangiogenic-drugs.